News NHS England extends deadline for med tech, digital innovatio... Innovation and Technology tariff deadline extended to 16 August
News Otsuka preps for July decision on centanafadine for ADHD The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
